Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations.  Blood.  134:5051-5051. 2019
2018 Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease.  Blood.  132:2506-2519. 2018
2018 Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined FlĪ²3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML.  Blood.  132:3949-3949. 2018
2015 Lateral Gene Transfer Contributing to Leukemogenesis.  Blood.  126:1235-1235. 2015
2014 Administration of a Tryptophan Metabolite, Indole-3-Carboxaldehyde, Reduces Graft Versus Host Disease Morbidity and Mortality and Enhances Gastrointestinal Barrier Function in a Murine Model of Allogeneic Bone Marrow Transplantation.  Blood.  124:2420-2420. 2014
2014 Similar Survival for Patients Undergoing Reduced-Intensity Total Body Irradiation (TBI) Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia 2014
2013 Blocking VIP Signaling Abrogates Upregulation Of PD1 and Increases Proliferation Of Allo-Reactive T-Cells In a Mixed Lymphocyte Reaction.  Blood.  122:1041-1041. 2013
2013 Pharmacological Inhibition Of Semi-Direct Alloantigen Presentation and The Generation Of Cross-Dressed Antigen Presenting Cells: A Novel approach To Limit Graft Versus Host Disease Following Allogeneic Hematopoetic Stem Cell Transplantation.  Blood.  122:294-294. 2013
2013 Similar Survival for Patients Undergoing Reduced-Intensity TBI Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia 2013
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Research Overview

  • AML

    • Principal Investigator On

  • Private Grant  awarded by DELTA-FLY PHARMA INC 2021 - 2024

    • Investigator On

  • Private Grant  awarded by AMGEN, INC.^ 2020 - 2024
  • Private Grant  awarded by INCYTE CORPORATION 2020 - 2024
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2024
  • Private Grant  awarded by CHIMERIX, INC. 2021 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2021 - 2024
  • Private Grant  awarded by ABBVIE INC 2021 - 2024
  • Private Grant  awarded by BLUEPRINT MEDICINES CORPORATION 2021 - 2024
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2021 - 2024
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2021 - 2024
  • Private Grant  awarded by MARKER THERAPEUTICS INC 2021 - 2024
  • Private Grant  awarded by FORTY SEVEN, INC. 2020 - 2023
  • Private Grant  awarded by CTI BIOPHARMA CORP 2020 - 2022
  • Private Grant  awarded by MARKER THERAPEUTICS INC 2021

    • Education And Training

  • Bachelor of Medicine & Surgery (MBBS) in Family Medicine Residency Program, Sikkim Manipal University of Health/Medical and Technology Science 2011
  • University of Minnesota, Residency 2014
  • Emory University School of Medicine, Postdoctoral Fellowship 2014

    • Full Name

  • Sravanti Rangaraju